1. Home
  2. CRBU vs PFX Comparison

CRBU vs PFX Comparison

Compare CRBU & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBU
  • PFX
  • Stock Information
  • Founded
  • CRBU 2011
  • PFX 2010
  • Country
  • CRBU United States
  • PFX United States
  • Employees
  • CRBU N/A
  • PFX N/A
  • Industry
  • CRBU Medicinal Chemicals and Botanical Products
  • PFX Finance: Consumer Services
  • Sector
  • CRBU Health Care
  • PFX Finance
  • Exchange
  • CRBU Nasdaq
  • PFX Nasdaq
  • Market Cap
  • CRBU 93.0M
  • PFX 101.2M
  • IPO Year
  • CRBU 2021
  • PFX N/A
  • Fundamental
  • Price
  • CRBU $1.07
  • PFX $49.00
  • Analyst Decision
  • CRBU Strong Buy
  • PFX
  • Analyst Count
  • CRBU 4
  • PFX 0
  • Target Price
  • CRBU $8.50
  • PFX N/A
  • AVG Volume (30 Days)
  • CRBU 943.1K
  • PFX 1.8K
  • Earning Date
  • CRBU 05-08-2025
  • PFX 05-06-2025
  • Dividend Yield
  • CRBU N/A
  • PFX 2.92%
  • EPS Growth
  • CRBU N/A
  • PFX N/A
  • EPS
  • CRBU N/A
  • PFX 5.09
  • Revenue
  • CRBU $9,918,000.00
  • PFX $24,036,577.00
  • Revenue This Year
  • CRBU N/A
  • PFX $10.51
  • Revenue Next Year
  • CRBU $161.81
  • PFX N/A
  • P/E Ratio
  • CRBU N/A
  • PFX $9.63
  • Revenue Growth
  • CRBU N/A
  • PFX 15.02
  • 52 Week Low
  • CRBU $0.66
  • PFX $44.32
  • 52 Week High
  • CRBU $3.00
  • PFX $57.40
  • Technical
  • Relative Strength Index (RSI)
  • CRBU 57.50
  • PFX 40.01
  • Support Level
  • CRBU $0.98
  • PFX $48.75
  • Resistance Level
  • CRBU $1.21
  • PFX $51.50
  • Average True Range (ATR)
  • CRBU 0.10
  • PFX 0.78
  • MACD
  • CRBU 0.02
  • PFX -0.00
  • Stochastic Oscillator
  • CRBU 68.23
  • PFX 16.67

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

About PFX PhenixFIN Corporation

PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

Share on Social Networks: